TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $5.84 billion. The enterprise value is $5.79 billion.
Important Dates
The last earnings date was Monday, May 5, 2025, before market open.
Earnings Date | May 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 145.82 million shares outstanding. The number of shares has increased by 9.66% in one year.
Current Share Class | 145.82M |
Shares Outstanding | 145.82M |
Shares Change (YoY) | +9.66% |
Shares Change (QoQ) | +1.58% |
Owned by Insiders (%) | 7.29% |
Owned by Institutions (%) | 71.72% |
Float | 135.13M |
Valuation Ratios
The trailing PE ratio is 168.22 and the forward PE ratio is 34.49. TG Therapeutics's PEG ratio is 0.30.
PE Ratio | 168.22 |
Forward PE | 34.49 |
PS Ratio | 14.79 |
Forward PS | 12.04 |
PB Ratio | 24.05 |
P/TBV Ratio | 24.48 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | 0.30 |
Financial Ratio History Enterprise Valuation
EV / Earnings | 147.83 |
EV / Sales | 14.98 |
EV / EBITDA | 96.67 |
EV / EBIT | 96.75 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.
Current Ratio | 4.02 |
Quick Ratio | 2.91 |
Debt / Equity | 1.07 |
Debt / EBITDA | 4.10 |
Debt / FCF | n/a |
Interest Coverage | 2.10 |
Financial Efficiency
Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.
Return on Equity (ROE) | 19.70% |
Return on Assets (ROA) | 7.26% |
Return on Invested Capital (ROIC) | 9.79% |
Return on Capital Employed (ROCE) | 12.05% |
Revenue Per Employee | $1.14M |
Profits Per Employee | $115,828 |
Employee Count | 338 |
Asset Turnover | 0.75 |
Inventory Turnover | 0.41 |
Taxes
In the past 12 months, TG Therapeutics has paid $2.59 million in taxes.
Income Tax | 2.59M |
Effective Tax Rate | 6.21% |
Stock Price Statistics
The stock price has increased by +142.35% in the last 52 weeks. The beta is 1.94, so TG Therapeutics's price volatility has been higher than the market average.
Beta (5Y) | 1.94 |
52-Week Price Change | +142.35% |
50-Day Moving Average | 37.46 |
200-Day Moving Average | 31.48 |
Relative Strength Index (RSI) | 64.97 |
Average Volume (20 Days) | 1,848,711 |
Short Selling Information
The latest short interest is 22.57 million, so 15.48% of the outstanding shares have been sold short.
Short Interest | 22.57M |
Short Previous Month | 23.11M |
Short % of Shares Out | 15.48% |
Short % of Float | 16.70% |
Short Ratio (days to cover) | 7.33 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $386.39 million and earned $39.15 million in profits. Earnings per share was $0.24.
Revenue | 386.39M |
Gross Profit | 337.80M |
Operating Income | 59.82M |
Pretax Income | n/a |
Net Income | 39.15M |
EBITDA | 59.87M |
EBIT | 59.82M |
Earnings Per Share (EPS) | $0.24 |
Full Income Statement Balance Sheet
The company has $276.24 million in cash and $254.58 million in debt, giving a net cash position of $21.66 million or $0.15 per share.
Cash & Cash Equivalents | 276.24M |
Total Debt | 254.58M |
Net Cash | 21.66M |
Net Cash Per Share | $0.15 |
Equity (Book Value) | 237.29M |
Book Value Per Share | 1.63 |
Working Capital | 484.30M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$61.03 million and capital expenditures -$70,000, giving a free cash flow of -$61.10 million.
Operating Cash Flow | -61.03M |
Capital Expenditures | -70,000 |
Free Cash Flow | -61.10M |
FCF Per Share | -$0.42 |
Full Cash Flow Statement Margins
Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.
Gross Margin | 87.43% |
Operating Margin | 15.48% |
Pretax Margin | 10.80% |
Profit Margin | 10.13% |
EBITDA Margin | 15.49% |
EBIT Margin | 15.48% |
FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -9.66% |
Shareholder Yield | -9.66% |
Earnings Yield | 0.67% |
FCF Yield | -1.05% |
Dividend Details Analyst Forecast
The average price target for TG Therapeutics is $40.80, which is 1.85% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $40.80 |
Price Target Difference | 1.85% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 36.90% |
EPS Growth Forecast (5Y) | 100.29% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside | |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.
Last Split Date | Apr 30, 2012 |
Split Type | Reverse |
Split Ratio | 0.0177777:1 |
Scores
TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.
Altman Z-Score | 3.66 |
Piotroski F-Score | 3 |